The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression [PDF]
Acta Biochimica et Biophysica Sinica, 2022 Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),is the currently recommended first-line therapy for advanced EGFR-mutant lung cancer, and understanding the mechanism of resistance is the key to formulating therapeutic ...
Ren Shengnan +7 more
doaj +4 more sources
Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line [PDF]
Cancer Medicine, 2020 We aimed to explore the molecular substrate underlying EGFR‐TKI resistance and investigate the effects of N‐acetylcysteine (NAC) on reversing EGFR‐TKI resistance.
Jun Li +5 more
doaj +5 more sources
Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. [PDF]
PLoS ONE, 2015 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, are effective for non-small cell lung cancer (NSCLC) patients with EGFR mutations. However, these patients eventually develop resistance to EGFR-TKI.
Mei-Chuan Tang +6 more
doaj +6 more sources
ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC [PDF]
Frontiers in Pharmacology, 2018 Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable ...
Hongbo Zhao +6 more
doaj +5 more sources
HDGF promotes gefitinib resistance by activating the PI3K/AKT and MEK/ERK signaling pathways in non-small cell lung cancer [PDF]
Cell Death Discovery, 2023 Hepatoma-derived growth factor (HDGF) expression is associated with poor prognosis in non-small cell lung cancer (NSCLC); however, whether HDGF affects gefitinib resistance in NSCLC remains unknown.
Shuyan Han +12 more
doaj +3 more sources
HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer [PDF]
Acta Biochimica et Biophysica Sinica, 2022 Non-small cell lung cancer (NSCLC) ranks the first in incidence and mortality among malignant tumors in China. Molecular targeted therapies such as gefitinib, an oral inhibitor of the epidermal growth factor receptor tyrosine kinase, have shown ...
Lei Tianyao +5 more
doaj +3 more sources
The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer [PDF]
Mediators of Inflammation, 2023 Background. Gefitinib resistance remains a major problem in the treatment of lung cancer. However, the underlying mechanisms involved in gefitinib resistance are largely unclear. Methods.
Puwei Song +4 more
doaj +3 more sources
IGFBP2/ITGA5 promotes gefitinib resistance via activating STAT3/CXCL1 axis in non-small cell lung cancer [PDF]
Cell Death and DiseaseThere is a paucity of comprehensive knowledge pertaining to the underlying mechanisms leading to gefitinib resistance in individuals diagnosed NSCLC harboring EGFR-sensitive mutations who inevitably develop resistance to gefitinib treatment within six ...
Hengxiao Lu +7 more
doaj +3 more sources
EBioMedicine, 2018 The epidermal growth factor receptor (EGFR) is known to play a critical role in non-small cell lung cancer (NSCLC). Constitutively active EGFR mutations, including in-frame deletion in exon 19 and L858R point mutation in exon 21, contribute about 90% of ...
Yiu To Yeung +9 more
doaj +4 more sources
BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells [PDF]
BMC Cancer, 2023 Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation often obtain de novo resistance or develop secondary resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), which restricts the clinical benefit for the
Yaya Yu +10 more
doaj +3 more sources